Company Encyclopedia
View More
name
Pasithea Therapeutics
KTTA.US
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia.
1.906 T
KTTA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock

    Dec 2 (Reuters) - Pasithea Therapeutics Corp:* PASITHEA THERAPEUTICS ANNOUNCES CLOSING OF $60 MILLION PUBLIC OFFERING OF COMMON STOCK Source text: Further company coverage:

    Reuters·
    US
    KTTA
    +0.89%
    Reuters·
    US
    KTTA
    +0.89%

    Pasithea Therapeutics Director Lawrence Steinman Reports Acquisition of Common Shares

    Lawrence Steinman, Director of Pasithea Therapeutics, has acquired common shares of the company. This information was published by Pasithea Therapeutics via the U.S. SEC's EDGAR system. The news is generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    KTTA
    +0.89%
    Reuters·
    US
    KTTA
    +0.89%

    Pasithea Therapeutics CEO Tiago Marques Reports Acquisition of Common Shares

    Tiago Marques, CEO and Director of Pasithea Therapeutics, reported acquiring common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system. This AI-generated news brief by Public Technologies is for informational purposes only and not financial advice. The original content was published by Pasithea Therapeutics on December 01, 2025.

    Reuters·
    US
    KTTA
    +0.89%
    Reuters·
    US
    KTTA
    +0.89%

    Dir Dumesnil Buys 33,333 ($25K) Of Pasithea Therapeutics Corp [KTTA]

    Dumesnil Simon Director of Pasithea Therapeutics Corp [KTTA] filed a Form 4 on December 1, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/28/25TransactionPurchaseShares33,333Price$0.75Value$25,000Ending Holdings: 35,833 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    KTTA
    +0.89%
    Reuters·
    US
    KTTA
    +0.89%

    Pasithea Therapeutics Director Simon Dumesnil Acquires Common Shares

    Simon Dumesnil, Director of Pasithea Therapeutics Corporation, has acquired common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system.

    Reuters·
    US
    KTTA
    +0.89%
    Reuters·
    US
    KTTA
    +0.89%
    © 2025 Longbridge｜Disclaimer